IP Library Patent Application 13659831
Patent Application
App. No. 13/659,831

METHODS OF BREAST CANCER DETECTION

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/659,831
Abstract

Methods of diagnosing breast cancers are provided. The methods include analyzing the expression patterns of biomarkers in a plurality of cells to distinguish between invasive and non-invasive cancers, usual and atypical hyperplasias, and basal-like breast cancers. Breast cancers are diagnosed based upon different combinations of the biomarkers found in nipple aspirate fluid.

Claims (30)

1 .- 22 . (canceled)

23 . A method of classifying a breast cancer, comprising:

a) contacting a cell of a nipple aspirate fluid sample absorbed onto an absorbent paper with antibodies that bind to CK5, CK14, CK7, CK18, and p63, wherein the absorbent paper is sized to cover a nipple;

b) detecting binding of one or more of the antibodies to said cell; and

c) classifying the cancer based upon the binding pattern of the primary antibodies;

wherein the cell derived from the nipple aspirate fluid (NAF) sample is not a tissue.

24 . The method of claim 23 , wherein the absorbent paper is from about 1.0 to about 3.0 inches in diameter and from about 0.01 to about 0.1 inches thick.

25 . The method of claim 23 , wherein detecting binding of the one or more antibodies further comprises staining the cells with a stain selected from among horseradish peroxidase, alkaline phosphatase, diaminobenzidine, Fast Red, hematoxylin, eosin and a combination thereof.

26 . The method of claim 23 , further comprising washing the absorbent paper and collecting the effluent.

27 . The method of claim 23 , wherein the absorbent paper comprises microcellulose, mixed cellulose ester, or nitrocellulose.

28 . The method of claim 23 , wherein the absorbent paper is a device as illustrated in FIG. 1 .

29 . The method of claim 23 , further comprising classifying the breast cancer as basal-like if an anti-CK5 antibody, an anti-CK14 antibody, and optionally an anti-p63, primary antibody binds to the cell.

30 . The method of claim 23 , further comprising classifying the breast cancer as luminal if (i) an anti-CK7 antibody and an anti-CK18 primary antibody bind to the cell, and (ii) an anti-CK5 antibody, and anti-CK14 antibody, and an anti-p63 antibody do not bind to the cell.

31 . The method of claim 23 , further comprising classifying the breast cancer as usual ductal hyperplasia if an anti-CK5 antibody, an anti-CK14 antibody, an anti-CK7 antibody, an anti-CK18 antibody, and an anti-p63 primary antibody bind to the cell.

32 . The method of claim 23 , further comprising classifying the cancer as atypical ductal hyperplasia if (i) the anti-CK7 antibody and anti-CK18 antibody, and optionally the anti-p63 antibody, bind to the cell, and (ii) the anti-CK5 antibody and anti-CK14 antibody do not bind to the cell.

33 . The method of claim 23 , further comprising classifying the cancer as invasive if (i) the sample comprises more than one cell and (i) the ratio of cells binding the anti-CK5 antibody, anti-CK14 antibody, and anti-p63 antibody to cells binding the anti-CK7 antibody and anti-CK18 antibody is less than or equal to an invasive control.

34 . The method of claim 23 , further comprising classifying the cancer as non-invasive if: (i) the sample comprises more than one cell, and (ii) the ratio of cells binding the anti-CK5 antibody, anti-CK14 antibody, and anti-p63 antibody to cells binding the anti-CK7 antibody and anti-CK18 antibody is greater than or equal to a non-invasive control.

35 . (canceled)

36 . A composition comprising (a) at least one cell derived from nipple aspirate fluid absorbed onto an absorbent paper comprising microcellulose, mixed cellulose ester, or nitrocellulose for absorbing a nipple aspirate fluid sample, wherein the absorbent paper is sized to cover a nipple; and (b) antibodies that bind to an antigens on a cell in the nipple aspirate fluid sample, wherein the antigens are selected from: CK5, CK14, CK7, CK18, p63, CK7 and CK18.

37 . A system for classifying a breast cancer, comprising:

a) an absorbent paper comprising microcellulose, mixed cellulose ester, or nitrocellulose for absorbing a nipple aspirate fluid sample, wherein the absorbent paper is sized to cover a nipple; and

b) antibodies that bind to an antigens on a cell in the nipple aspirate fluid sample, wherein the antigens are selected from: CK5, CK14, CK7, CK18, p63, CK7 and CK18.

38 . The system of claim 37 , further comprising a light microscope or an automated system for visualizing the antibodies bound to a cell in the nipple aspirate fluid sample.

39 . The system of claim 37 , wherein the absorbent paper is from about 1.0 to about 3.0 inches in diameter and from about 0.01 to about 0.1 inches thick.

40 . The system of claim 37 , further comprising means for visualizing the antibodies bound to the cell in the nipple aspirate fluid sample.

41 . The system of claim 40 , wherein the means for visualizing the antibodies bound to the cell in the nipple aspirate fluid sample is one or more stains.

42 . The system of claim 41 , wherein the stain is selected from horseradish peroxidase, alkaline phosphatase, diaminobenzidine, Fast Red, hematoxylin, eosin or a combination thereof.

43 . (canceled)

44 . The system of claim 37 , further comprising: an optionally networked computer processing device configured to perform executable instructions; and a computer program, the computer program comprising a software module executed by the computer processing device to apply a model or algorithm for analyzing said cells.

45 .- 52 . (canceled)

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE CHANGE OF NAME PREVIOUSLY RECORDED AT REEL: 051783 FRAME: 0477. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Nov 10, 2020
From: ATOSSA GENETICS INC.
To: ATOSSA THERAPEUTICS, INC.
Reel/Frame 054372/0976 →
CHANGE OF NAME Recorded Feb 3, 2020
From: ATOSSA GENETICS INC.
To: ATOSSA THERAPEUTICS, INC.
Reel/Frame 051783/0477 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2013
From: QUAY, STEVEN C.; CHEN, SHU-CHIH
To: ATOSSA GENETICS, INC.
Reel/Frame 029600/0197 →